On January 7, 2025 Halda Therapeutics, a biotechnology company developing a novel class of cancer therapies called RIPTAC (Regulated Induced Proximity TArgeting Chimeras) therapeutics, reported it will present at the 43rd annual J.P. Morgan Healthcare Conference taking place on January 13-16, 2025 in San Francisco, CA (Press release, Halda Therapeutics, JAN 7, 2025, View Source [SID1234649491]). Christian Schade, President and Chief Executive Officer of Halda, will provide a corporate overview, including recent product pipeline progress and upcoming milestones.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation details are:

Date: Tuesday, January 14
Time: 3:00 p.m. PT
Location: The Westin St. Francis